Shamik J. Parikh - 04 Apr 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Medical Officer
Signature
/s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
04 Apr 2022
Net transactions value
$0
Form type
4
Filing time
05 Apr 2022, 16:40:31 UTC
Next filing
12 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +144,927 $0.000000 144,927 04 Apr 2022 Common Stock 144,927 $6.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on April 4, 2023, after which 1/48 of the option will become exercisable on the 4th of each month through August 4, 2026.